The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages : the AML15 and 16 trial experience
Ponatinib and inhibition of the PI3K/Akt/mTOR pathway induces cell death and protective autophagy in TKI-resistant CML stem/progenitor cells : 2
Identification of the key survival pathways underlying CML stem cell resistance to TKIs : 3
Identification of novel therapeutic targets to eliminate chronic myeloid leukaemia stem cells : 4
A comprehensive diagnostic approach improves the diagnostic accuracy of invasive fungal disease (IFD) in adult haemato-oncology patients undergoing HSCT or high dose chemotherapy - results of the King's Prospective Aspergillosis Study (NCT00816088) : 5
BK virus-associated haemorrhagic cystitis is associated with GVHD and significant morbidity post haematopoietic stem cell transplant : 6
Favorable outcomes in elderly and high-risk patients with AML and MDS following T-cell depleted reduced intensity conditioned allogeneic stem cell transplantation : 7
Continued absence of transfusion-associated graft versus host disease despite failures to provide irradiated products to patients at risk - more than a decade of data from SHOT : 8
Is presence of ETV6/RUNX1 an independent prognostic marker for relapse risk? Retrospective analysis of ETV6/RUNX1-positive patients treated on MRCUKALL2003, at Birmingham Children's Hospital, UK : 9
Performing immunophenotyping by flow cytometry on bone marrow trephines from paediatric patients : 10
Potentially modifiable risk factors associated with neurocognitive deficits in adolescents with sickle cell disease and normal brain MRI : 11
Elevated Trib2 with Notch1 activation in pediatric/ adult T-ALL : 12
Th1 and Th2 cytokine levels are increased in murine models of human sickle cell anaemia maintained on a high protein calories feed : 13
Transposon driven leukaemogenesis follows an accelerated Darwinian-like evolution in a mouse model of Npm1c+ acute myeloid leukaemia : 14
Rs10974944 germline polymorphism, JAK2 V617F somatic mutation, haematological parameters, and morbidity in 49,488 individuals from the general population : 15
Adoptive therapy with redirected MHC class I-restricted antigen-specific regulatory T cells is a potential novel cellular therapy for graft-versus-host disease : 16
A predictive phenolog approach identifies that And1 and Sec13 are required to maintain genome stability : 17
Thrombocytopenia with Absent Radii (TAR) syndrome is cause by compound inheritance of low-frequency regulatory SNPs and a rare null mutation in exon-junction complex subunit RBM8A : 18
Nine predicted unpaired cysteine residues in von Willebrand factor are essential for VWF secretion : 19
XAMOS : a non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophylaxis after major orthopaedic surgery of the hip and knee
Novel MHC-peptide-T cell receptor interfaces are necessary for inhibitor formation in mild/moderate haemophilia A secondary to missense mutation genotypes : 21
The mechanisms underlying the positive inotropic effect of activated protein C : 22
Presenting D-dimer and early symptom severity are independent predictors of post thrombotic syndrome following a first deep vein thrombosis : 23
Clinical and laboratory characteristics of 31 subjects with heritable dysfibrinogenaemia : 24
Warfarin dose prediction in children using pharmacogenetics information : 25
The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL) : results of the randomised UK National Cancer Research Institute (NCRI) trial
Mutations in SF3B1, but not NOTCH1, are independently associated with survival in the UK CLL4 trial : 27
Minimal residual disease is highly predictive of outcome in myeloma : results from MRC Myeloma IX
The significance of deletion architecture, ATM mutational status and genomic complexity in 11q deleted CLL : 29
First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007 : 30
Chronic lymphocytic leukaemia lymph node T-cells show evidence of chronic antigenic stimulation and a skewed T-cell receptor repertoire : 31
Efficacy and safety of conventional-dose lenalidomide followed by low-dose maintenance lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) : updated results from a UK phase II study
The CDK inhibitor CR8 diminishes NFκB signalling in CLL cells : 33
Alpha thalassaemia and the severity of Plasmodium falciparum infection in microcytic children from the Ashanti region of Ghana : 34
Hypermethylation of 28S ribosomal RNA in β-thalassemia : 35
Implementation of nurse authorisation of blood components in NHS Scotland : 36
Too much blood, too quickly : avoiding hazards associated with transfusion-associated circulatory overload (TACO) identified by SHOT reporting
Evaluating the introduction of entonox for bone marrow aspirations : 38
National comparative audit of red cell transfusion in medical patients : 39
Patients with biochemical iron overload and low risk or negative HFE genotypes are a diagnostic and therapeutic challenge in clinical haematology : 40
Detection of the BRAF V600E mutation in hairy cell leukaemia and other mature B-cell malignancies : a single centre evaluation of over 400 cases
Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial : 42
The development of humanized DARC FYB(ES) transgenic mouse : 43
The impact of mutant level on clinical outcome in acute myeloid leukaemia differs according to the mutated gene : 44
Germline activating JAK2-mutation in a family with hereditary thrombocytosis : 45
Patients with haematological malignancy requiring intensive care treatment : a 5 year review
Utility of blood cultures in febrile patients in a BCSH Level 4 Centre : 47
Haematology readmission : marker of poor prognosis, not poor quality care
Generic e-mail laboratory advice service to general practitioners provides prompt, effective and popular means of communication : 49
An audit of the quality of consent forms for chemotherapy in a combined Haematology and Oncology Day Unit : 50
The demographic profile of patients receiving regular cobalamin (B12) therapy in a local general practice surgery : 51
Digital morphology : the UKNEQAS(H) scheme for continuing professional development 4 years experience
The last resort in pyrexia of unknown origin : an audit of bone marrow specimens submitted for microbiological analysis at St George's Hospital, 2006-2011
Sysmex XN analysers - a novel modular blood cell counting system : 54
Abstract Withdrawn : 55
IFN stimulation can influence early stem cell fate decisions : 56
Demand management in a district general hospital laboratory - lessons learned from audit of B12 and folate requests : 57
Improving the immediate management of febrile neutropenia in a district general hospital : 58
An update on development of a quality assurance programme for the reporting of bone marrow morphology in the North Trent Haemato-oncology Diagnostic Service : 59
Do all medical patients need a routine coagulation sample on admission to a medical admissions unit? A prospective audit at a district general hospital : 60
An investigation of the role of CXCL1-CXCR2 signalling in haemopoietic stem cell quiescence : 61
Bordetella holmesii in asplenic patients : a new pathogen
Production of a gallery for the WHO for morphological identification of haematopoietic cells, for use in developing nations : 63
Use of intravenous iron for management of iron deficiency in a haematology day care setting : 64
Haemoglobin measurement by blood gas analysers in acute hospital point of care settings : 65
An outreach monoclonal gammopathy of undetermined significance monitoring system in a large district general hospital : 66
Transition to an integrated reporting system for bone marrow biopsies from patients with suspected haematological malignancy - experience in North Central London/West Essex : 67
Treating ‘haematophobia’ in medical students : 68
Iron deficiency anaemia in pregnancy - is it a concern? : 69
Can estimated GFR replace EDTA GFR for haematology patients receiving nephrotoxic chemotherapy agents? : 70
Estimation of fetomaternal haemorrhage using Kleihauer test in the National Maternity Hospital : 71
The value of computerised VTE assessments : findings from retrospective audit of 2474 non-consecutive electronic patient records in a VTE exemplar centre
Gammaplex® IVIg in subjects with chronic idiopathic (immune) thrombocytopenic purpura : 73
VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children : 74
Assessment of haemostasis in malaria and HIV infected subjects in Nnewi, South East : 75
An audit of venousthromboembolism (VTE) risk assessments in the obstetric department at King's College Hospital (KCH) : 76
Post-thrombotic syndrome is an independent determinant of quality of life following a first deep vein thrombosis : 77
Two previously unreported mutations, Cys849Phe and Cys858Ser, identified in patients with type 2N VWD in five families from different regions of Iran : 78
Problems in the use of prothrombin complex concentrate for reversal of anticoagulation in actual clinical practice : 79
Outcomes from root cause analysis of hospital-associated thrombosis over twelve months : a single centre experience
Prothrombin/phosphatidyl serine antibodies in patients with antiphospholipid antibodies : 81
Significantly higher mortality associated with hospital acquired thrombosis compared with community acquired thrombosis : 82
Review of heritable thrombophilia testing in Northern Ireland (NI) : 83
Expanding the GAPP project - feasibility of remote platelet phenotyping : 84
The management of patients admitted with suspected pulmonary embolus : 85
Impaired primary haemostasis in severe sepsis despite elevated von Willebrand factor : 86
Haemostasis point of care testing in theatres and cardiac catheter laboratories : 87
The changing portfolio of UK NEQAS for Blood Coagulation : 88
Usefulness of Q scans in diagnostic algorithm of pulmonary embolism : a university hospital audit
An audit of hospital-acquired venous thromboembolism (HAT) rates according to medical specialty at the Great Western Hospital Swindon : 90
Cardiac procedure and surgery in haemophiliacs - a case series from a single haemophilia centre : 91
Assessing risk for venous thrombo-embolism (VTE) in early pregnancy : implementation of a schema and the impact on care by referrals to a specialist clinic
Abstract Withdrawn : 93
Dental procedures in patients with bleeding disorders and the cost effectiveness of ‘make your own’ tranexamic acid mouthwash : 94
Smaller fixed doses of prothrombin complex concentrate are effective for reversal of warfarin related over-anticoagulation and reduce costs significantly : results of a retrospective audit in the settings of a district general hospital
A single-centre retrospective study of prothrombin complex concentrate (octaplex) use : 96
Computerised patient records enhance communication, audit potential and patient safety in a large haemophilia comprehensive care centre : 97
Single centre experience of reduced intensity rituximab in acquired haemophilia A : 98
High incidence of venous thromboembolism in newly diagnosed lymphoma patients : 99
The influence of ABO(H) blood group on the clotting potential of whole blood and plasma component therapy from healthy blood donors : 100
Investigation of FXIII deficiency : is it improving? data from UK NEQAS for blood coagulation
Investigation of a prolonged APTT : 102
Therapeutic dalteparin dosing in obese patients : 103
Venous-thromboembolism in patients with plaster casts for lower leg fracture : experience in a large teaching hospital trust
Thrombophilia testing in the west of Scotland : an audit against the 2010 BCSH guideline
Preventing venous thrombosis in patients admitted to a district general hospital for medical and surgical treatments : 106
The NFIL3 transcription factor is preferentially expressed in BCR-independent mature B-cell malignancy : 107
Toll-like receptor-1 triggering on multiple myeloma cells modulates their adhesion to bone marrow stromal cells : 108
Targeting chronic lymphocytic leukaemia survival and proliferation with bioactive cell penetrating peptides : 109
Characterising CD31-CD38 signalling in chronic lymphocytic leukaemia : 110
An audit on the use of flow cytometry as a means to detect haematological malignancy in lymph node biopsies : 111
A systematic investigation of the cell surface proteome of chronic lymphoytic leukaemia : 112
c-MET is expressed in the nucleus of normal Tlymphocytes and is induced during progression through the cell cycle commitment point : 113
An untimely reminder of an uncommon complication : severe veno-occlusive disease with extensive hepatocyte necrosis following autologous stem cell transplantation for relapsed Hodgkin's lymphoma - case report and review of the literature
High-dose methylprednisolone and rituximab treatment in refractory and cytopenic chronic lymphocytic leukaemia patients : 115
Abnormal serum free light chain ratio predicts inferior overall survival in mantle cell lymphoma : 116
Haemophagocytic lymphohistiocytosis following fludarabine /cyclophosphamide chemotherapy for chronic lymphocytic leukaemia : 117
Interim analysis results of a phase II trial of single agent ofatumumab in the treatment of relapsed/refractory mantle cell lymphoma : 118
First UK experience of BTK inhibitor PCI-32765 - dramatic responses in relapsed/refractory mantle cell lymphoma : 119
Single centre experience of secondary CNS involvement in rituximab treated high IPI diffuse large B cell lymphoma : 120
Reversibility of renal insufficiency secondary to myeloma - a single institution experience : 121
Alemtuzumab based therapy in high risk chronic lymphocytic leukaemia : 122
Single centre experience with bortezomib second line and beyond for myeloma : 123
An audit on the use of lenalidomide in patients with myeloma : 124
EBV viraemia after reduced intensity conditioning haematopoetic stem cell transplant incorporating alemtuzumab and its association with post transplant lymphoproliferative disorder : 125
Audit of adequacy of bone marrow trephines reported by the haemato-oncology diagnostic service : 126
Administration of bortezomib : authorising treatment on days 4, 8 and 11 of each cycle prior to reviewing haematology results
Encouraging long-term survival outcomes in chronic lymphocytic leukaemia (CLL) : a regional centre experience
First line treatment of mantle cell lymphoma with high dose cytarabine and rituximab : 129
The comprehensive geriatric assessment needs of older people with lymphoma : 130
Accuracy in data collection of deaths due to myeloma in one centre : 131
Management without radiotherapy may be an acceptable approach for stage 1 follicular lymphoma : 132
Primary care management of stage A0 chronic lymphocytic leukaemia is safe and effective : 133
The bi-specific antibody blinatumomab (MT103) induces apoptotic cell death in CLL B-cells via the activation of autologous T-cells : 134
Factors affecting relative dose intensity in patients with Hodgkin lymphoma (HL) receiving doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) without granulocyte-colony stimulating factor (G-CSF) support : 135
Outcome of secondary CNS lymphoma following autologous stem cell transplantation : 136
CD80-IL2 expressing myeloma cells for immune gene therapy of multiple myeloma : 137
Expanding the therapeutic potential of bromodomain inhibition in haematological cancer : 138
Study of cell death in acute myeloid leukaemia cell lines following vorinostat treatment : 139
Identification of prospective roles of ankyrin repeat and SOCS box proteins (ASBs) in acute myeloid leukaemia : 140
Canonical Wnt signalling plays a key role in influencing mesodermal commitment and primitive erythropoiesis : 141
Modulation of TGF-β1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells : 142
JAK2 V617F false negative rate in the UK NEQAS LI programme : 143
ASXL1 mutations are infrequent in young patients with primary acute myeloid leukaemia : 144
MicroRNAs expression on MDS with −7/7q deletion : 145
Mechanism of Trib2 mediated degradation of C/EBP-α in acute myelogenous leukaemia : 146
The ABCB1 3’UTR polymorphism (rs3842) is functionally significant in AML via effects on miR374a binding : 147
Investigating synergism of Mcl-1 inhibition with first line therapies for leukaemia : 148
Specific inhibition of autophagy enhances TKI-induced death in CML cells : 149
Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells : 150
BCR-ABL inhibition induces expression of autophagy related genes in primary CML cells : 151
Posaconazole prophylaxis obviates the need for empirical escalation of antifungal therapy during chemotherapy for acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) : 152
Late toxicity of imatinib mesylate during therapy for chronic myeloid leukaemia (CML) : what happens if you stop imatinib? - a BSH update for 2012
Cytogenetic abnormalities in acute myeloid leukaemia - the west of Scotland experience; early death continues to be significant in acute promyelocytic leukaemia : 154
Time to initiation of intensive therapy has no impact on outcome in non-acute promyelocytic acute myeloid leukaemia. Experience from the West of Scotland Cancer Network : 155
An audit of the investigation and management of suspected invasive fungal infection in a level 3 haematology unit : 156
JAK2 v617f testing in the Northern Region, a review of 803 patient records : 157
Evaluation of frequency of monitoring of chronic myeloid leukaemia patients in a general haematology department compared to European LeukaemiaNet guidelines : 158
Outcome following relapse of acute myeloid leukaemia - a single centre experience : 159
A population study demonstrating that the availability of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia : 160
Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia : 161
Novel design of VALOR, a phase 3 trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukaemia : 162
Factors affecting outcome of salvage chemotherapy with FLAG+/− idarubicin for adults with relapsed/refractory AML : 163
Addition of arsenic to ATRA and idarubicin upfront in APML : experience from a single centre
Does iron chelation therapy improve survival and reduce infections in patients with myelodysplastic syndrome? : 165
Treatment of acute myeloid leukaemia in the elderly : a retrospective analysis
Sweets syndrome and its association with myelodysplastic syndrome (MDS) - a single centre retrospective analysis of 27 cases : 167
A UK single centre experience of 5-azacitidine in patients with myeloid malignancies, prior to NICE approval - a retrospective evaluation of 113 patients : 168
Outcomes from allogeneic stem cell transplant compared to consolidation chemotherapy in acute myeloid leukaemia (AML) patients with FLT3 internal tandem duplications (ITD) - a single transplant centre study : 169
Audit of telephone calls to an anticoagulant clinic : 170
An audit of the appropriateness of VTE prophylaxis prescribing on a general surgical ward : 171
A 6 months audit looking at the timing of haematology Nurse Specialists involvement for people with a newly diagnosed haematological malignancy : 172
High risk haematology at a low risk antenatal clinic : 173
A retrospective analysis of the diagnosis of type 1 von Willebrand disease in children : is the bleeding score helpful?
Cutaneous manifestations in childhood leukaemia : 175
No prognostic impact of CRLF2 deregulation in childhood acute lymphoblastic leukaemia treated according to UK ALL 2003 protocol : 176
The impact of pain on executive functioning in young people with sickle cell anaemia : 177
Implementation of the new born screening programme for haemoglobinopathies in Scotland : results of the first year
Abstract Withdrawn : 179
A cohort study of sleep disordered breathing in preschool children with sickle cell disease : 180
Comparison of PCR & flow cytometry MRD detection in patients with relapse acute lymphoblastic leukaemia (ALL) treated in ALLR3 trial : 181
Molecular versus flow cytometric MRD analysis - is there an explanation for discrepancies? : 182
West Midlands population-based report of childhood AML outcome over a 6 years period : 183
Iron deficiency anaemia as a cause of severe anaemia (Hb 5 ≤ g/dl) in children ≤16 years; results from an East London Institution : 184
Automated exchange transfusions for sickle cell disease are safe and feasible using peripheral access in the paediatric population : 185
Serious adverse events of UKALL 2003 : a single centre's experience shows incidence significantly higher than previously reported
A new haemoglobin variant with an extended beta chain due to an insertion of CCAGT at the position 375-376 : 187
Addition of hydroxyurea to transfusion programme to treat progressive cerebral vasculopathy : 188
Acute pain management protocols in adult sickle cell patients - audit of observation frequency following administration of opiate analgesia : 189
Use of individualised acute pain management protocols in adult sickle cell patients - a single centre experience : 190
Reduced fertility potential in female patients with sickle cell disease : 191
Audit of assessment and management of patients presenting with sickle vaso-occlusive crisis to City Hospital Birmingham : 192
Sickle cell crisis : a 9-year audit of length of stay at the Whittington Hospital
Clinical audit : compliance with iron chelation therapy in adult thalassaemia patients
Predictors of length of stay and time to readmission in adult patients with sickle cell disease - a single institution experience in the UK : 195
Fifty-two percentage reduction in thalassaemia major patients with high liver iron concentration using FerriScan monitoring at the Whittington Hospital : 196
West of Scotland audit on granulocyte transfusions : 197
Immunoglobulin project : a comparison of different immunoglobulin preparations
Fresh frozen plasma for abnormal coagulation tests - are we getting it right? : 199
Transfusion safety in patients requiring irradiatied blood components : audit findings lead to change of practice in chemotherapy prescribing
Errors in administration of anti-D immunoglobulin to prevent RhD haemolytic disease of the fetus and newborn : mothers and babies put at risk
Is centralization of pathology services really the way forward? : 202
Use of FFP for paediatric patients : issuing MB or not MB?
An audit of red-cell usage and transfusion thresholds for haemato-oncology in-patients in a UK tertiary centre : 204
Audit on the compliance with the guidelines for the use of irradiated blood components : 205
Detection of incorrect blood component transfusions utilising electronic bedside verification : 206
Testing patients for immunoglobulin a deficiency : time to think again?
D positive donor kidneys transplanted into D negative recipients : do recipients form anti-D as a result?
Audit of the use of prothrombin complex concentrate (octaplex) in a large tertiary hospital : 209
Alloantibody formation in regularly transfused young patients (aged ≤ 21 years) with sickle cell disease - a single centre review : 210
UK NEQAS LI BCR-ABL1 Quantitation Programme : impact of UK guidelines for BCR-ABL1 transcript quantitation in chronic myeloid leukaemia
The Canadian man with two blood groups : 212
An audit of BCSH guidelines : are we minimising the risk of transfusion-associated graft-versus-host-disease?
Peripheral blood stem cell mobilisation during apheresis may be a significant contributor to harvesting yield : 214
The role of targeted antenatal screening in foetal and neonatal alloimmune thrombocytopenia (FNAIT) : 215
Pre-hospital care standard operating procedure - use of human prothrombin complex (octaplex®) : 216
The efficiency of COBE spectra apheresis machine in collecting PBSC : a comparison between manual and auto mode of function
Selected myeloma patients benefit from renal transplantation : 218
First remission autologous stem cell transplantation (ASCT) with BCNU/thiotepa shows good response in patients with CNS lymphoma : 219
Autologous stem cell transplantation in patients with severe renal impairment. A single centre experience : 220
Autologous stem cell transplantation can improve the quality of response in lymphoplasmacytic lymphoma/waldenstrom macroglobulinaemia with a median time to best response of 5 months : 221
Vitamin D deficiency at the time of HSCT may be safely reversed by high dose vitamin : 222
Exploiting CD8β mutations which increase TCR avidity to improve the function of genetically modified T cells for immunotherapy : 223
Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+ T cells : 224
Reduced immuno-suppression : an effective strategy in the management of EBV reactivation in patients following allogeneic stem cell transplant